Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 952-958

  Larsen, Robert A ^a   Pappas, Peter G ^b   Perfect, John ^c   Aberg, Judith A ^d   Casadevall, Arturo ^e   Cloud, Gretchen A ^b   James, Robert ^f   Filler, Scott ^g   Dismukes, William E ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f Rho Federal Systems Division Inc   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18B7; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; BACKACHE; CEREBROSPINAL FLUID; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; FEMALE; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRACRANIAL HYPERTENSION; MALE; MYALGIA; NAUSEA; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SIDE EFFECT; TREATMENT OUTCOME; URTICARIA; VOMITING;

ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIGENS, FUNGAL; AREA UNDER CURVE; CRYPTOCOCCUS NEOFORMANS; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; MENINGITIS, CRYPTOCOCCAL; MICE;

EID: 14744279814     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.952-958.2005     Document Type: Article

References (54)

1. Bennett, J. E., W. E. Dismukes, R. J. Duma, G. Medoff, M. A. Sande, H. Gallis, J. Leonard, B. T. Fields, M. Bradshaw, H. Haywood, Z. A. McGee, T. R. Cate, C. G. Cobbs, J. F. Warner, and D. W. Alling. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N. Engl. J. Med. 301:126-131.
2. Berry, A. J., M. G. Rinaldi, and J. R. Graybill. 1992. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. 36:690-692.
3. Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34:19-30.
4. Bourne, D. 1995. Mathematical modeling of pharmacokinetic data. Technomic Publishing Company, Inc., Lancaster, Pa.
5. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L. A. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
6. 5a. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1997. Serious adverse event reference manual. National Institute of Allergy and Infectious Diseases, Rockville, Md.
7. Dong, Z. M., and J. W. Murphy. 1995. Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun. 63:2632-2644.
8. Dong, Z. M., and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrphils. J. Clin. Investig. 97:689-698.
9. Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:1114-1120.
10. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
11. Feldmesser, M., and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790-799.
12. Feldmesser, M., J. Mukherjee, and A. Casadevall. 1996. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob. Chemother. 37:617-622.
13. Gibaldi, M. 1991. Biopharmaceutics and clinical pharmcokinetics, 4th ed., Lea & Febiger, Malvern, Pa.
14. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448-3453.
15. Gordon, M. A., and A. Casadevall. 1995. Serum therapy for cryptococcal meningitis. Clin. Infect. Dis. 21:1477-1479.
16. Gordon, M. A., and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114:373-378.
17. Graybill, J. R., M. Hague, and D. J. Drutz. 1981. Passive immunization in murine cryptococcosis. Sabouraudia 19:237-244.
18. Harrison, T. S., A. S. Nong, and M. Levitz. 1997. Induction of human immunodeficiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J. Infect. Dis. 176:485-491.
19. Hirano, A., H. M. Zimmerman, and S. Sevine. 1964. The fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage. Am. J. Pathol. 46:1-19.
20. Hirano, A., H. M. Zimmerman, and S. Sevine. 1964. Fine structure of cerebral fluid accumulation. V. Transfer of fluid from extracellular compartments in acute phase of cryptococcal polysaccharide lesions. Arch. Neurol. 11:632-641.
21. Hirano, A., H. M. Zimmerman, and S. Sevine. 1965. Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria. Arch. Neurol. 12:189-196.
22. Hirano, A., H. M. Zimmerman, and S. Sevine. 1965. The fine structure of cerebral fluid accumulation. VII. Reactions of astrocytes to cryptococcal polysaccharide implantation. J. Neuropathol. Exp. Neurol. 24:386-396.
23. Khazaeli, M. B. 1989. Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. Hybridoma 8:231-239.
24. Khazaeli, M. B., R. M. Conry, and A. F. LoBuglio. 1994. Human immune response to monoclonal antibodies. J. Immunol. 15:42-53.
25. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol. 129:1675-1680.
26. Larsen, R. A., S. A. Bozzette, B. E. Jones, D. Haghighat, M. A. Leal, D. Forthal, M. Bauer, J. G. Tilles, J. A. McCutchan, and J. M. Leedom. 1994. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19:741-745.
27. Larsen, R. A., M. A. Leal, and L. S. Chan. 1990. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 113:183-187.
28. Lee, S. C., Y. Kress, D. W. Dickson, and A. Casadevall. 1995. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. J. Neuroimmunol. 62:43-52.
29. Lendvai, N., and A. Casadevall. 1999. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype. J. Infect. Dis. 180:791-801.
30. Lendvai, N., X. W. Qu, W. Hsueh, and A. Casadevall. 2000. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J. Immunol. 164:4367-4374.
31. Macher, A. M., J. E. Bennett, J. E. Gadek, and M. M. Frank. Complement depletion in cryptococcal sepsis. J. Immunol. 120:1686-1690.
32. McFadden, D. C., O. Zaragoza, and A. Casadevall. 2004. Immunoreactivity of cryptococcal antigen is not stable under prolonged incubations in human serum. J. Clin. Microbiol. 42:2786-2788.
33. McLean, G. R., M. Torres, N. Elguezabal, A. Nakouzi, and A. Casadevall. 2002. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169:1379-1386.
34. Milefchik, E., M. Leal, R. Haubrich, S. Bozzette, J. Tilles, J. Leedom, J. A. McCutchan, and R. A. Larsen. 1997. A phase II dose escalation trial of high dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. Program Abstr. 4th Conf. Retrovir. Opportunistic Infect.
35. Monari, C., A. Casadevall, C. Retini, F. Baldelli, F. Bistoni, and A. Vecchiarelli. 1999. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 13:653-660.
36. Mukherjee, J., A. Casadevall, and M. D. Scharff. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1105-1116.
37. Mukherjee, J., M. Feldmesser, M. D. Scharff, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob. Agents Chemother. 39:1398-1405.
38. Mukherjee, J., L. A. Pirofski, M. D. Scharff, and A. Casadevall. 1993. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:3636-3640.
39. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
40. Mukherjee, J., L. S. Zuckier, M. D. Scharff, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580-587.
41. Mukherjee, S., M. Feldmesser, and A. Casadevall. 1996. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J. Infect. Dis. 173:1222-1231.
42. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
43. Mukherjee, S., S. Lee, J. Mukherjee, M. D. Scharff, and A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62:1079-1088.
44. Murphy, J. W., and G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5:896-901.
45. Pettoello-Mantovani, M., A. Casadevall, T. R. Kollmann, A. Rubinstein, and H. Goldstein. 1992. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339:21-23.
46. Pettoello-Mantovani, M., A. Casadevall, P. Smarnworawong, and H. Goldstein. 1994. Enhancement of HIV type 1 infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Res. Hum. Retrovir. 10:1079-1087.
47. Retini, C., A. Vecchiarelli, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64:2897-2903.
48. Robinson, P. A., M. Bauer, M. A. Leal, S. G. Evans, P. D. Holtom, D. A. Diamond, J. M. Leedom, and R. A. Larsen. 1999. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 28:82-92.
49. Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkey, S. E. Thompson, A. M. Sugar, C. U. Tuazon, J. F. Fisher, et al. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.
50. Savoy, A. C., D. M. Lupan, P. B. Manalo, J. S. Roberts, A. M. Schlageter, L. C. Weinhold, and T. R. Kozel. 1997. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun. 65:1800-1807.
51. van der Horst, C. M., M. S. Saag, G. A. Cloud, R. J. Hamill, J. R. Graybill, J. D. Sobel, P. C. Johnson, C. U. Tuazon, T. Kerkering, B. L. Moskovitz, W. G. Powderly, W. E. Dismukes, et al. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337:15-21.
52. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38:407-417.
53. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:2846-2849.
54. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infect. Immun. 63:2919-2923.